Cgp 38560

For research use only. Not for therapeutic Use.

  • CAT Number: I004927
  • CAS Number: 122088-76-0
  • Molecular Formula: C39H64N6O9S2
  • Molecular Weight: 825.09
  • Purity: ≥95%
Inquiry Now

CGP 38560(Cat No.:I004927)is a selective antagonist of the adenosine A2A receptor, a G-protein-coupled receptor involved in regulating neurotransmission and inflammation. By blocking the A2A receptor, CGP 38560 can modulate dopaminergic activity, which has potential therapeutic applications in conditions such as Parkinson’s disease, where adenosine A2A receptor overactivity is implicated. Preclinical studies have shown that CGP 38560 may improve motor function and reduce symptoms in animal models of Parkinson’s disease. It is also being investigated for its potential benefits in neurodegenerative disorders, cognitive function, and inflammation-related diseases. Further clinical trials are needed for validation.


Catalog Number I004927
CAS Number 122088-76-0
Synonyms

Cgp 38560; Cgp38560; Cgp-38560.;L-Valinamide, N-(2-(((1,1-dimethylethyl)sulfonyl)methyl)-1-oxo-3-phenylpropyl)-L-histidyl-3-cyclohexyl-L-alanyl-N-butyl-, (R)-, monomethanesulfonate

Molecular Formula C39H64N6O9S2
Purity ≥95%
Target Renin Inhibitor
Solubility Soluble in DMSO, not in water
Storage 0 - 4 °C for short term or -20 °C for long term
IUPAC Name (2S)-N-[(2S)-2-amino-3-cyclohexylpropanoyl]-N-[(2S)-2-[[(2R)-2-benzyl-3-tert-butylsulfonylpropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]-2-(butylamino)-3-methylbutanamide;methanesulfonic acid
InChI InChI=1S/C38H60N6O6S.CH4O3S/c1-7-8-19-41-33(26(2)3)37(48)44(35(46)31(39)21-28-17-13-10-14-18-28)36(47)32(22-30-23-40-25-42-30)43-34(45)29(20-27-15-11-9-12-16-27)24-51(49,50)38(4,5)6;1-5(2,3)4/h9,11-12,15-16,23,25-26,28-29,31-33,41H,7-8,10,13-14,17-22,24,39H2,1-6H3,(H,40,42)(H,43,45);1H3,(H,2,3,4)/t29-,31-,32-,33-;/m0./s1
InChIKey XXPFSPNMUAZMMO-CRNPUGFUSA-N
SMILES CCCCN[C@@H](C(C)C)C(=O)N(C(=O)[C@H](CC1CCCCC1)N)C(=O)[C@H](CC2=CN=CN2)NC(=O)[C@@H](CC3=CC=CC=C3)CS(=O)(=O)C(C)(C)C.CS(=O)(=O)O
Reference

</br>1: Hanessian S, Claridge S, Johnstone S. The power of visual imagery in synthesis planning. Stereocontrolled approaches to CGP-60536B, a potent renin inhibitor. J Org Chem. 2002 Jun 14;67(12):4261-74. PubMed PMID: 12054962.</br></br>

Request a Quote